文献速递自身炎症与 IgG4 相关病其他结缔组织病

Still病中补体激活与II型干扰素信号相关

Complement Activation Linked to Type II Interferon Signaling in Still Disease.
PubMed 文献 · Arthritis Rheumatol · 2026-08-25

该研究通过转录组学、蛋白质组学和体外实验评估Still病(SD)的补体激活。SD起病时单核细胞补体级联富集,经典补体基因C1QB/C1QC显著上调,活性SD患者C1q、C3a、C5a和终末补体复合物蛋白水平升高且经典补体功能活性增强。全血C1QB/C1QC表达与IFN相关标志物(IL-18、CXCL9、CXCL10)相关,重组IFN-γ诱导单核细胞C1q,而C1q增强CD8+ T细胞产生IFN-γ,形成正反馈环路。结论:SD以补体激活为特征,C1q显著上调并与IFN-γ/II型信号密切相关。

要点

  • SD起病时单核细胞补体级联富集,经典补体基因C1QB/C1QC显著上调。
  • 活性SD患者C1q、C3a、C5a和终末补体复合物蛋白升高,经典补体功能活性增强。
  • C1q与IFN-γ形成正反馈环路,补体激活与II型干扰素信号紧密关联。

核心结论

  • SD以补体激活为特征,C1q显著上调并与IFN-γ/II型信号密切相关。

研究设计与样本

  • 研究采用转录组学、蛋白质组学和体外实验方法评估SD中的补体激活。
  • 对健康供者(n=15)、非全身型JIA(n=8)、SD起病(n=19)和缓解(n=18)患者及巨噬细胞活化综合征(n=2)患者进行单核细胞RNA测序。
  • 对SD患者(活动期n=41,非活动期n=33)和JIA患者(n>600)进行全血NanoString分析补体和干扰素相关基因表达。
  • 用Luminex和ELISA检测补体产物和炎症介质,在SD(活动期n=30,非活动期n=67)和JIA血清(n=12)中评估功能性补体活性。
  • 体外实验检测单核细胞C1q诱导和补体介导的CD8+ T细胞活化。

主要发现

  • SD起病时单核细胞转录组分析显示补体级联富集,与缓解期患者相比调整P=3.7×10-36,位列前10上调通路。
  • 与缓解期SD和JIA患者相比,起病SD中经典补体基因C1QB/C1QC显著上调。
  • 活动性SD患者C1q、C3a、C5a和终末补体复合物蛋白水平升高,功能性经典补体活性增强。
  • 全血C1QB/C1QC表达与IFN相关标志物包括白细胞介素-18、CXCL9和CXCL10相关。
  • 重组IFN-γ诱导单核细胞C1q,而C1q增强CD8+ T细胞产生IFN-γ,支持正反馈环路。

临床怎么用

  • 在SD患者中可关注补体激活标志物(如C1q、C3a、C5a)与IFN-γ信号的相关性。
  • C1q与IFN-γ的正反馈环路提示补体通路可能作为SD的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. METHODS: Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing of monocytes was performed in healthy donors (n = 15), those with nonsystemic juvenile idiopathic arthritis (JIA; n = 8), patients with SD at onset (n = 19) and remission (n = 18), and those with macrophage activation syndrome (n = 2). Whole-blood NanoString analysis of complement and interferon (IFN)-related gene expression was conducted in patients with SD (active n = 41, inactive n = 33) and JIA (n > 600). Complement products and inflammatory mediators were measured by Luminex and enzyme-linked immunosorbent assay. Functional complement activity was evaluated in SD (active n = 30, inactive n = 67) and JIA sera (n = 12). In vitro assays examined monocytic C1q induction and complement-mediated CD8+ T cell activation. RESULTS: Transcriptomic analysis of monocytes from patients with SD at onset revealed enrichment of the complement cascade compared with patients in remission (adjusted P = 3.7 × 10-36), ranking among the top 10 up-regulated pathways. Classical complement genes (C1QB/C1QC) were markedly up-regulated in onset SD compared with patients with remission SD and JIA. Patients with active SD showed increased C1q, C3a, C5a, and terminal complement complex protein levels, with enhanced functional classical complement activity. Whole-blood C1QB/C1QC expression correlated with IFN-related markers, including interleukin-18, CXCL9, and CXCL10. Recombinant IFN-γ induced monocytic C1q, whereas C1q enhanced IFN-γ production by CD8+ T cells, supporting a feed-forward loop. CONCLUSION: SD is characterized by complement activation with marked up-regulation of C1q, which is closely linked to IFN-γ/type II signaling.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Huijsmans FMCH, Thalheim T, Bodelón A, et al. Complement Activation Linked to Type II Interferon Signaling in Still Disease. Arthritis Rheumatol. 2026. PMID: 42640011. doi:10.1002/art.70307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。